- Home
- RLYB vs RANI Comparison
RLYB vs RANI Comparison
Compare RLYB & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- RANI
- Stock Information
- Founded
- RLYB 2018
- RANI 2012
- Country
- RLYB United States
- RANI United States
- Employees
- RLYB N/A
- RANI N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- RANI Medicinal Chemicals and Botanical Products
- Sector
- RLYB Health Care
- RANI Health Care
- Exchange
- RLYB Nasdaq
- RANI Nasdaq
- Market Cap
- RLYB 24.1M
- RANI 23.2M
- IPO Year
- RLYB 2021
- RANI 2021
- Fundamental
- Price
- RLYB $0.59
- RANI $0.49
- Analyst Decision
- RLYB Hold
- RANI Strong Buy
- Analyst Count
- RLYB 2
- RANI 4
- Target Price
- RLYB N/A
- RANI $7.75
- AVG Volume (30 Days)
- RLYB 385.4K
- RANI 439.7K
- Earning Date
- RLYB 11-06-2025
- RANI 11-13-2025
- Dividend Yield
- RLYB N/A
- RANI N/A
- EPS Growth
- RLYB N/A
- RANI N/A
- EPS
- RLYB N/A
- RANI N/A
- Revenue
- RLYB $761,000.00
- RANI $1,200,000.00
- Revenue This Year
- RLYB N/A
- RANI N/A
- Revenue Next Year
- RLYB N/A
- RANI N/A
- P/E Ratio
- RLYB N/A
- RANI N/A
- Revenue Growth
- RLYB 154.51
- RANI N/A
- 52 Week Low
- RLYB $0.22
- RANI $0.39
- 52 Week High
- RLYB $1.24
- RANI $3.75
- Technical
- Relative Strength Index (RSI)
- RLYB 55.28
- RANI 44.01
- Support Level
- RLYB $0.58
- RANI $0.47
- Resistance Level
- RLYB $0.61
- RANI $0.51
- Average True Range (ATR)
- RLYB 0.04
- RANI 0.04
- MACD
- RLYB -0.00
- RANI -0.00
- Stochastic Oscillator
- RLYB 73.86
- RANI 25.21
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.